By Goutham Ravipati, MD; Konstantinos Charitakis, MD, FSCAI

Introduction

Approximately 10%-15% of patients undergoing percutaneous coronary intervention (PCI) have active or prior cancer. This population presents a uniquely difficult combination of increased bleeding risk, elevated thrombotic risk, thrombocytopenia, drug-to-drug interactions, and frequent need for time-sensitive oncologic therapy, biopsy, or surgery.^1-3 These competing risks make the duration and intensity of dual-antiplatelet therapy (DAPT) after PCI particularly important.

In this Tip of the Month, we review the evidence and practical guidance for abbreviated DAPT in patients with active cancer undergoing PCI. The key concept is that “early DAPT discontinuation” should usually mean shortened DAPT followed by single antiplatelet therapy (SAPT), rather than complete cessation of all antiplatelet therapy, unless complete cessation is specifically required because of bleeding, severe thrombocytopenia, or an urgent oncologic procedure.

Why Cancer Patients Need Individualized Bleeding-Reduction Strategies

Cancer and atherosclerotic coronary artery disease (CAD) overlap because they share multiple risk factors, including tobacco use, obesity, diabetes, sedentary lifestyle, and inflammation. Cancer itself and several cancer therapies can also accelerate vascular injury through endothelial dysfunction, inflammation, plaque progression, vasospasm, and dysregulated hemostasis.^2,3

Historically, patients with active cancer were excluded or underrepresented in major DAPT trials. Therefore, most evidence guiding antiplatelet strategy comes from high-bleeding-risk (HBR) trials, registries, meta-analyses, and expert consensus.^1,3,4 Although many patients with active cancer meet HBR criteria, they should not be viewed only as bleeding-risk patients. They often also have high ischemic risk because of acute coronary syndrome (ACS) presentation, complex CAD, cancer-associated thrombosis, inflammatory vascular injury, and interruptions in antiplatelet therapy required for cancer care.

Bleeding-reduction strategies begin before stent implantation. When clinically feasible, the interventional cardiologist should clarify the cancer treatment timeline, anticipated thrombocytopenia, need for surgery or biopsy, active bleeding status, drug interactions, expected survival, and goals of care. Procedural strategies should include radial access when feasible, meticulous access-site management, avoidance of unnecessary large-bore access, optimization of anemia and thrombocytopenia in collaboration with oncology and hematology, careful anticoagulant dosing, avoidance of glycoprotein IIb/IIIa inhibitors in severe thrombocytopenia, and a PCI strategy designed for the likelihood that DAPT may need to be abbreviated.^3,4

Pre-PCI Planning: Assume DAPT May Need to Be Abbreviated

For patients with active cancer, the minimum feasible duration of DAPT should be discussed with the oncology team before stent implantation whenever the clinical situation allows. The interventionalist should determine whether upcoming chemotherapy, surgery, biopsy, radiation therapy, expected platelet nadir, or anticoagulation needs may require antiplatelet interruption. If a patient cannot reasonably complete at least four weeks of DAPT, the need for PCI, the extent of revascularization, and alternatives to stenting should be reconsidered in a multidisciplinary discussion.

When PCI is necessary, contemporary drug-eluting stents (DES) should generally be preferred over bare-metal stents, even in patients expected to need short DAPT. Newer-generation DES have better safety and efficacy and have been studied with abbreviated DAPT strategies.^1,3,7,8 Intravascular imaging with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) should be strongly considered to optimize lesion preparation, stent expansion, stent apposition, and edge assessment because an optimal PCI result is especially important when antiplatelet therapy may need to be shortened.³

Platelet Count and Antiplatelet Selection

The 2022 European Society of Cardiology (ESC) cardio-oncology guideline provides practical platelet thresholds: Aspirin can generally be considered when the platelet count is above 10,000/µL in the absence of active bleeding, and DAPT with aspirin plus clopidogrel can be considered when the platelet count is above 30,000/µL.⁴ In thrombocytopenic patients, clopidogrel is generally preferred over ticagrelor or prasugrel, particularly when platelet counts are below 50,000/µL.⁴

The choice and duration of antiplatelet therapy should also account for expected platelet recovery, active bleeding, chemotherapy interactions, renal or hepatic dysfunction, need for oral anticoagulation, coronary anatomy, lesion location, stent result, ACS versus PCI for stable angina presentation, and the timing of planned oncologic procedures. Potent P2Y12 inhibitors may be appropriate in selected patients with high thrombotic risk and acceptable platelet counts, but aspirin plus clopidogrel remains the most practical default DAPT regimen for many cancer patients with thrombocytopenia.^3,4

Evidence Supporting Abbreviated DAPT in Cancer and HBR Populations

A 2024 patient-level meta-analysis of four controlled HBR DES studies evaluated patients with cancer treated with one-month DAPT. Compared with HBR patients without cancer, patients with cancer did not have higher rates of myocardial infarction (MI), stent thrombosis, or target-lesion revascularization after abbreviated DAPT. Cancer patients had more bleeding overall, but much of the excess bleeding occurred after the first month, when many patients were already receiving SAPT, suggesting that cancer-related bleeding risk is not driven solely by the initial DAPT period.¹

These data support a practical approach: If PCI is required in a patient with active cancer, the procedure should be planned with the expectation that DAPT may need to be abbreviated. In selected patients after optimized contemporary DES PCI, the target duration is commonly one to three months, with at least four weeks of aspirin plus clopidogrel whenever feasible, followed by SAPT when bleeding risk or oncologic urgency is high.^1,3,7,8 This strategy should not be applied mechanically; ischemic risk, PCI complexity, ACS presentation, stent result, bleeding risk, and cancer-treatment timing should drive the final decision.

ACS vs. PCI for Stable Angina

ACS

For the general ACS population after PCI, default guideline-directed therapy remains 12 months of DAPT, often with ticagrelor or prasugrel preferred over clopidogrel when bleeding risk is acceptable.^5,6 However, active cancer commonly justifies deviation from this default because of thrombocytopenia, active bleeding risk, urgent oncologic procedures, drug interactions, and the need to avoid delaying cancer therapy.

In cancer patients with ACS and thrombocytopenia, aspirin plus clopidogrel is often the preferred DAPT regimen when DAPT is feasible. Patients who tolerate the first month of DAPT but remain HBR may be considered for de-escalation to clopidogrel or transition to SAPT, depending on bleeding risk, ischemic risk, and oncologic urgency.^5,6 Longer DAPT should still be considered when ischemic risk is high and bleeding risk is manageable, including ACS with high thrombus burden, complex PCI, left main or proximal left anterior descending (LAD) stenting, recurrent MI, prior stent thrombosis, diabetes with complex disease, or suboptimal stent expansion or apposition.

PCI for Stable Angina

For PCI performed for stable angina, the default DAPT duration is generally shorter than after ACS, and contemporary chronic coronary disease and stable coronary disease guidance supports shortened DAPT followed by P2Y12 inhibitor monotherapy or SAPT in selected HBR patients.^7,8 In active cancer patients undergoing PCI for stable angina, abbreviated DAPT for one month, followed by SAPT, is often reasonable when the PCI result is optimized and bleeding risk or oncologic urgency is high. Longer therapy may be appropriate when ischemic risk is high and bleeding risk is acceptable.

Practical Approach to Abbreviated DAPT in Active Cancer

Conclusion

Patients with active cancer undergoing PCI require individualized antiplatelet planning because they have both HBR and high thrombotic risk. Contemporary evidence supports abbreviated DAPT after optimized DES PCI in selected patients, most commonly one to three months and, when interruption is unavoidable, at least four weeks whenever feasible, followed by SAPT. The safest approach is to plan antiplatelet therapy before PCI in collaboration with oncology; select contemporary DES rather than bare-metal stents when stenting is necessary; optimize the PCI result with IVUS or OCT; use aspirin plus clopidogrel as the default regimen in thrombocytopenic patients; and reassess bleeding, ischemic, and oncologic priorities at four weeks to three months.

References

1. Campos CM, Mehran R, Capodanno D, et al. Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials. Circ Cardiovasc Interv. 2024 Apr;17(4).
2. Tsigkas G, Vakka A, Apostolos A, et al. Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review. J Cardiovasc Dev Dis. 2023 Mar;10(4):135.
3. Zhang L, Iliescu C, Ferencik M, et al. Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2026;153(10).
4. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361.
5. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13).
6. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826.
7. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023;82(9):833-955.
8. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537.